125 related articles for article (PubMed ID: 16739368)
1. [Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Dohmen W; Fuchs W
MMW Fortschr Med; 2005 Apr; 147 Suppl 1():21-5. PubMed ID: 16739368
[TBL] [Abstract][Full Text] [Related]
2. [Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Dohmen W; Fuchs W
MMW Fortschr Med; 2005 Mar; 147(9):39. PubMed ID: 15794353
[No Abstract] [Full Text] [Related]
3. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
Fennerty MB; Johanson JF; Hwang C; Sostek M
Aliment Pharmacol Ther; 2005 Feb; 21(4):455-63. PubMed ID: 15709997
[TBL] [Abstract][Full Text] [Related]
4. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
[TBL] [Abstract][Full Text] [Related]
5. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Inadomi JM; McIntyre L; Bernard L; Fendrick AM
Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
[TBL] [Abstract][Full Text] [Related]
6. An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube.
Devlin JW; Bakshi A; Bungay K; Olsen KM
Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1603-11. PubMed ID: 17206948
[TBL] [Abstract][Full Text] [Related]
7. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
Earnest DL; Dorsch E; Jones J; Jennings DE; Greski-Rose PA
Am J Gastroenterol; 1998 Feb; 93(2):238-43. PubMed ID: 9468251
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
Mulder CJ; Westerveld BD; Smit JM; Oudkerk Pool M; Otten MH; Tan TG; van Milligen de Wit AW; de Groot GH;
Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):649-56. PubMed ID: 12072599
[TBL] [Abstract][Full Text] [Related]
10. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.
Tsai HH; Chapman R; Shepherd A; McKeith D; Anderson M; Vearer D; Duggan S; Rosen JP;
Aliment Pharmacol Ther; 2004 Sep; 20(6):657-65. PubMed ID: 15352914
[TBL] [Abstract][Full Text] [Related]
12. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A
Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():24; discussion 25-7. PubMed ID: 12614304
[TBL] [Abstract][Full Text] [Related]
14. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Florent C
Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
[TBL] [Abstract][Full Text] [Related]
15. Lansoprazole versus omeprazole in the treatment of reflux esophagitis.
Vcev A; Stimac D; Vceva A; Rubinić M; Ivandić A; Ivanis N; Horvat D; Volarić M; Karner I
Acta Med Croatica; 1997; 51(3):171-4. PubMed ID: 9248117
[TBL] [Abstract][Full Text] [Related]
16. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
Baldi F; Morselli-Labate AM; Cappiello R; Ghersi S;
Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
[TBL] [Abstract][Full Text] [Related]
18. A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease.
Norman Hansen A; Bergheim R; Fagertun H; Lund H; Moum B
Int J Clin Pract; 2005 Jun; 59(6):665-71. PubMed ID: 15924594
[TBL] [Abstract][Full Text] [Related]
19. [Lansoprazole--profile of a new proton pump inhibitor].
Seifert E
Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
[TBL] [Abstract][Full Text] [Related]
20. [Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
Müller P; Fuchs W; Peifer-Weiss A; Simon B
Fortschr Med; 1998 Oct; 116(28):31-2. PubMed ID: 9844264
[No Abstract] [Full Text] [Related]
[Next] [New Search]
